Prelude Therapeutics (PRLD) Equity Ratio (2023 - 2026)
Prelude Therapeutics' Equity Ratio history spans 4 years, with the latest figure at 0.5 for Q1 2026.
- On a quarterly basis, Equity Ratio fell 31.13% to 0.5 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.5, a 31.13% decrease, with the full-year FY2025 number at 0.49, down 35.15% from a year prior.
- Equity Ratio hit 0.5 in Q1 2026 for Prelude Therapeutics, up from 0.49 in the prior quarter.
- Over the last five years, Equity Ratio for PRLD hit a ceiling of 0.85 in Q4 2023 and a floor of 0.49 in Q4 2025.
- Historically, Equity Ratio has averaged 0.71 across 4 years, with a median of 0.74 in 2025.
- Biggest five-year swings in Equity Ratio: fell 12.28% in 2024 and later plummeted 35.15% in 2025.
- Tracing PRLD's Equity Ratio over 4 years: stood at 0.85 in 2023, then fell by 12.28% to 0.75 in 2024, then plummeted by 35.15% to 0.49 in 2025, then rose by 3.57% to 0.5 in 2026.
- Business Quant data shows Equity Ratio for PRLD at 0.5 in Q1 2026, 0.49 in Q4 2025, and 0.62 in Q3 2025.